What is Biological E?
Biological E operates as a premier biopharmaceutical entity, specializing in the development and large-scale manufacturing of vaccines, injectable pharmaceuticals, and specialty biologic products. By prioritizing affordable healthcare access, the company bridges the gap between complex medical research and widespread public health implementation. Its market position is defined by a robust commitment to regulatory excellence and high-quality production standards, enabling it to serve both domestic and international markets effectively. Through strategic partnerships and a focus on infectious disease mitigation, Biological E remains a vital player in the global effort to enhance health security and pharmaceutical accessibility.
How much funding has Biological E raised?
Biological E has raised a total of $5M across 1 funding round:
Grant
$5M
Grant (2020): $5M with participation from Coalition for Epidemic Preparedness Innovations
Key Investors in Biological E
Coalition for Epidemic Preparedness Innovations
A global partnership launched to develop vaccines to stop future epidemics and ensure equitable access to immunization.
What's next for Biological E?
Looking ahead, the deployment of this capital will likely accelerate the expansion of Biological E's manufacturing footprint and research pipeline. As the company navigates the complexities of the post-pandemic landscape, the focus will remain on scaling production for essential vaccines and diversifying its portfolio of specialty biologics. By leveraging its established global partnerships, Biological E is well-positioned to capitalize on the growing demand for high-quality, affordable medical solutions, ensuring long-term growth and sustained impact on global health outcomes.
See full Biological E company page
